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LO-F.03 SURGICAL MANAGEMENT OF
METASTATIC COLON CANCER IN
ELDERLY: ANALYSIS OF THE
SURVEILLANCE, EPIDEMIOLOGY AND
END RESULTS (SEER) DATABASE
H. Khan1, A. Olszewski2 and P. Somasundar1
1Roger Williams Medical Center, Providence, RI;
2Pawtucket Memorial Hospital, Pawtucket, RHODE
ISLAND
Background: The objective of this study was to evaluate
survival after resection of primary tumor and/or metastatic
sites, by age and the extent of nodal spread, using the
population-based SEER registry.
Methods: We extracted data on pts diagnosed with colon
adenocarcinoma between 2000–2010 (N = 232,640). We
analyzed extent of nodal involvement (N0-2) in cases with
≥12 lymph nodes examined (LNE), identified stage IV pts
with recorded resection of primary tumor or of metastases.
Association of overall survival (OS) with metastatectomy
was evaluated in multivariable Cox models.
Results: Among 41,590 pts with stage IV cancer, 67%
underwent primary surgery and 11% metastatectomy. Older
pts were more likely to have <12 LNE, but also to have
N0 status when adequately staged (Table, P < .0001).
Metastatectomy (N = 4,506) was less common in older
patients (Table). OS after resection inversely associated with
age, nodal involvement, tumor grade and suboptimal staging
with <12 LNE (P < .0001). However, OS benefit of
metastatectomy was significant in all age groups except those
≥85 y old (Table) and was independent of the extent of nodal
spread (HR, 0.71, 0.68 and 0.77 for N0, N1 and N2 cases,
respectively) or tumor grade.
Conclusion: The survival advantage of metastatic site resec-
tion in colon cancer is present in ages up to 85 y. Adequate
nodal resection favorably correlates with survival after
metastatectomy, and older pts are more likely to be node-
negative at resection with ≥12 LNE. These results support
offering curative metastatectomy and resection of the
primary tumor in this age group.
LO-F.05 SURGICAL AND TOTAL COSTS
OF HEPATO-PANCREATO-BILIARY (HPB)
SURGERY FOR US PATIENTS
ENROLLED IN PRIVATE INSURANCE
J. R. Schubart, E. Schaefer, A. N. Kulaylat,
C. S. Hollenbeak and N. J. Gusani
Program For Liver, Pancreas, & Foregut Tumors, Penn
State College Of Medicine, Hershey, PA
Introduction: Costs of surgical care in private insurance
systems are not well understood. In high-complexity surgical
procedures, surgical and perioperative costs, as well as read-
mission and further therapies, are likely to drastically affect
total costs incurred.
Methods: The MarketScan® database, 2008–10, containing
claims for >56 million employees/dependents under private
insurance, was used to identify major pancreatectomy
(n = 2254) and hepatobiliary (n = 1702) surgery patients who
were enrolled >=120 days prior to surgery and after dis-
charge. “Total costs” represent all payments paid to the pro-
vider for services reported within this timeframe, inflated to
2010 dollars. We also measured all payments for the initial
surgery and subsequent hospital stay only (“surgical costs”).
Results: Median age was 53, with perioperative mortality of
2.1% (pancreas), and 1.5% (liver), respectively. Median post-
operative length-of-stay was 9 d for pancreatectomy and 6 d
for hepatectomy. Fewer pancreatectomy patients were dis-
charged to home compared to hepatectomy patients (70.9%
vs 85.1%). 120 d readmission rates were higher for pancre-
atic surgery (31.1%) than for hepatic surgery (22.7%). Mean
total costs were $105,200 (95% CI: $102,200-$108,200) for
pancreatectomy and $88,600 (95% CI: $85,800-$91,500) for
hepatectomy. Mean surgical costs were $70,700 for pancrea-
tectomy, representing 67% of total costs, while mean surgical
costs were $55,600 for hepatectomy, 63% of total costs.
Conclusion: This study reports costs for surgery patients in
private insurance. These patients are younger and likely to have
fewer co-morbidities than those covered by Medicare. Total cost
of surgical care was influenced largely by the index surgical
admission, representing 63–67% of the total costs of care.
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VB.01 ROBOTIC-ASSISTED
PANCREATODUODENECTOMY FOR
CANCER
E. Vicente, Y. Quijano, B. Ielpo, H. Duran, E. Diaz,
I. Fabra, C. Oliva, S. Olivares, R. Caruso, R. Ceron and
J. Plaza
Sanchinarro University Hospital, Madrid, MADRID
Background: Pancreatic surgery is a challenge for most
surgeons. This complexity is clearly increased with the use of
the minimally invasive techniques. However, Robotic system
may overcome some of the limitations of the laparoscopic
procedure.
Materials and Methods: In this video we show a case of
Robotic assisted duodeno-cephalic pancreatectomy.
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Results: We show the different Robotic surgical steps of the
pancreatoduodenectomy which includes the tumor resection
and robotic surgical reconstructions (biliary, pancreatic and
intestinal anastomosis).
Conclusion: This video shows the efficacy and feasibility of
robotic pancreatic surgery providing a three dimensional
imaging, a greater instrumental movement and tremor filter-
ing of the surgeon, thus reducing the minimally invasive
surgery related complexity.
VB.02 SYNCHRONOUS TOTAL
LAPAROSCOPIC RIGHT HEPATECTOMY
AND RIGHT HEMICOLECTOMY
S. Jayaraman
University Of Toronto, Toronto, ON
Synchronous resection of primary colon cancer and liver
metastases has been shown to be safe and effective in
selected cases. This video details the presentation of an
asymptomatic patient with a colon cancer originating in the
cecum as well as an isolated hepatic metastasis near the
bifurcation of the right anterior and posterior inflow pedicles.
In order to obtain total oncologic clearance, a right hepatec-
tomy and right hemicolectomy was indicated. The operation
begins with the hepatectomy being performed laparoscopi-
cally with out the aid of open or hand ports. Upon completion
of the hepatectomy, the right liver specimen is placed in
a large bag in the right upper quadrant. The laparoscopic
right hemicolectomy ensues including a medial approach
and high ligation of the ileocolic pedicle. Subsequently an
intracorporeal laparoscopic ileocolic anastomosis is per-
formed. Both the liver and colon specimen are removed
through a Pfannensteil incision. The final pathology showed
a pT3N1M1 colon cancer with all margins negative. The
patient was discharged on the ninth postoperative day with an
uneventful hospitalization. In one year follow up and after
completion of adjuvant therapy, there is no evidence of
recurrence.
VB.03 NEAR INFRARRED
TECHNOLOGY GIVES A NEW TOOL TO
THE SURGEONS TO IDENTIFY BILIARY
ANATOMY
F. Dip, M. Roy, C. Simpfendorfer, E. Lomenzo,
S. Szomstein and R. Rosenthal
Cleveland Clinic Florida, Weston, FLORIDA
Introduction: Fluorescence-guided surgery is a novel tech-
nology that could facilitate the recognition of bile duct struc-
tures. Using adequate fluorescent dye and appropriate
laparoscopic equipment, critical structures can be identified.
Method: The procedure begins with administration of a
single dose of 0.05 mg/kg of indocyanine green one hour
prior to surgery. A Storz® xenon light source and laparoscope
with a charge-coupled device that filters out light wave-
lengths except 830 nm with a specific 780 nm infrared light
source is used intraoperatively. The light of the laparoscope
can be easily changed to the infrared view using a pedal.
When illuminated by infrared light, the dye manifests fluo-
rescence. Abdominal inspection with standard trocar place-
ment is performed. The fluorescence system is then activated
using the pedal. Since the dye is excreted exclusively by the
liver it creates the biliary structures can be identified because
of fluorescence.
Results: This video demonstrates the feasibility of the tech-
nique using indocyanin green as described above. Visualiza-
tion of the cystic duct, hepatic ducts, accessory ducts and
main bile duct is shown using fluorescence.
Conclusion: Near infrared technology seems to be a fea-
sible and easy method to delineate the biliary tree anatomy in
real time.
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O-G.01 EARLY IDENTIFICATION OF
PATIENTS AT INCREASED RISK FOR
HEPATIC INSUFFICIENCY,
COMPLICATIONS, AND MORTALITY
AFTER MAJOR HEPATECTOMY
J. W. Etra1, M. H. Squires1, S. B. Fisher1, D. R. Rutz1,
B. Martin1, D. A. Kooby1, K. Cardona1, J. M. Sarmiento2,
C. A. Staley1, S. K. Maithel1 and M. C. Russell1
1Department Of Surgery, Division Of Surgical Oncology,
Winship Cancer Institute, Emory University, Atlanta,
GEORGIA; 2Department Of Surgery, Division Of General
And Gastrointestinal Surgery, Emory University, Atlanta,
GEORGIA
Background: A postoperative bilirubin >7 mg/dL is an
accepted definition of postoperative hepatic insufficiency
(PHI), as it is associated with increased complications and
mortality after hepatectomy. Early recognition of these
patients at increased risk may affect treatment strategy. Our
aim was to identify a surrogate marker for PHI early in the
postoperative course.
Methods: A single institution database of patients undergo-
ing major hepatectomy (≥3 segments) from 2000–2012 was
retrospectively reviewed. Preoperative, intraoperative, and
early postoperative factors were assessed for association with
any complications, major complications (Clavien Grade III-
V), and 90-day mortality.
Results: 607 patients undergoing major hepatic resection,
excluding bile duct reconstruction, were identified. Post-
operative complications and major complications occurred in
352(58%) and 136(22%) patients. 90-day mortality was 4%.
A postoperative day 3 (POD3) total bilirubin ≥3 mg/dL was
significantly (p < 0.001) associated with increased risk of
post-operative complications (76% vs 54%), major compli-
cations (46% vs 18%), and 90-day mortality (16% vs 2%;
Figure I). This association persisted on multivariate regres-
sion analysis for all 3 endpoints: any complications
(HR:1.98, 95%CI:1.10–3.54,p = 0.022), major complica-
tions (HR:3.18, 95%CI:1.90–5.32,p < 0.001), and 90-day
mortality (HR:8.11, 95%CI:3.00–21.92,p < 0.001; Table I).
A POD3 bilirubin ≥3 was the only early perioperative factor
associated with the development of a postoperative total bili-
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